Plus Therapeutics, Inc., announced that its abstract regarding lead investigational drug, Rhenium NanoLiposomes, was accepted to the 2020 Society for Neuro-Oncology Annual Meeting being held virtually on November 19-21, 2020.
AUSTIN, Texas, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announced that its abstract regarding lead investigational drug, Rhenium NanoLiposomes (RNL™), was accepted to the 2020 Society for Neuro-Oncology (SNO) Annual Meeting being held virtually on November 19-21, 2020.
“We are looking forward to updating the medical community on the latest data from our ReSPECT™ Phase 1 trial,” said Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. “Until then, we will continue to focus on completing ReSPECT trial enrollment and the chemistry and manufacturing controls required to advance RNL to the next step of clinical development.”
The Company will be providing a detailed interim safety, tolerability, dosing and efficacy data from its ReSPECT Phase 1 clinical trial of a novel radiotherapy, RNL, in adults with recurrent glioblastoma (GBM) after standard surgical, radiation, and chemotherapy treatment. GBM is a rare, incurable and fatal disease with a median survival of about nine months following recurrence despite the current standard of care.
ReSPECT is currently supported by an award from the National Cancer Institute. The Company plans to complete enrollment in the Phase 1 trial by the end of 2020 and in parallel will utilize its recently awarded U.S. Food and Drug Administration (FDA) Orphan Drug and Fast Track designations to determine the next steps for the program.
Additional details about the ReSPECT trial are available at clinicaltrials.gov (NCT01906385).
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at plustherapeutics.com and respect-trials.com.
About The Society for Neuro-Oncology
The Society for Neuro-Oncology exists to advance multi-disciplinary brain tumor research, education, and collaboration to drive discovery and improve patient care. Over 2,600 neuro-oncology professionals are anticipated to register for the 25th Annual Scientific Meeting and Education Day being held virtually on November 19-21, 2020. More information can be found at soc-neuro-onc.org.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements about: the Company’s potential to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers; the Company’s potential to develop drug candidates currently in its product pipeline; and the Company’s potential to develop additional drugs outside of its current pipeline. The forward-looking statements included in this press release are subject to a number of additional material risks and uncertainties, including but not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the U.S. FDA’s accelerated regulatory pathways; and the risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
Westwicke/ICR
(443) 377-4767
Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
Westwicke/ICR
(203) 856-4326
Terri.Clevenger@westwicke.com
